BioInformant - Stem Cell Industry News
@bioinformant.bsky.social
As the first and only market research firm to specialize in the stem cell industry, BioInformant.com is read by nearly 1 million readers per year. BioInformant has been cited by WSJ, Xconomy, and Vogue, as well as featured in Tony Robbin's book Life Force.
Clinical #StemCell Services: REPROCELL's experts in cell therapy manufacturing will take you through all the stages of your regenerative medicine project
www.reprocell.com/clinical-ste...
www.reprocell.com/clinical-ste...
October 6, 2025 at 5:00 PM
Clinical #StemCell Services: REPROCELL's experts in cell therapy manufacturing will take you through all the stages of your regenerative medicine project
www.reprocell.com/clinical-ste...
www.reprocell.com/clinical-ste...
Regenerelle® Issues Response to FDA Untitled Letter - bioinformant.com/regenerelle-...
Regenerelle®, a leader in Wharton’s Jelly Mesenchymal Stromal Cells (WJ-MSCs) & exosomes derived from WJ-MSCs, announced the public release of its full response to the U.S. FDA Untitled Letter dated May 22, 2023.
Regenerelle®, a leader in Wharton’s Jelly Mesenchymal Stromal Cells (WJ-MSCs) & exosomes derived from WJ-MSCs, announced the public release of its full response to the U.S. FDA Untitled Letter dated May 22, 2023.
September 10, 2025 at 1:58 AM
Regenerelle® Issues Response to FDA Untitled Letter - bioinformant.com/regenerelle-...
Regenerelle®, a leader in Wharton’s Jelly Mesenchymal Stromal Cells (WJ-MSCs) & exosomes derived from WJ-MSCs, announced the public release of its full response to the U.S. FDA Untitled Letter dated May 22, 2023.
Regenerelle®, a leader in Wharton’s Jelly Mesenchymal Stromal Cells (WJ-MSCs) & exosomes derived from WJ-MSCs, announced the public release of its full response to the U.S. FDA Untitled Letter dated May 22, 2023.
The Scalable Solution for 10X Exosome Yield: AgentV-DSP
AgentV™-DSP, a solution from RoosterBio, is designed to prevent filter fouling and deliver novel processing advantages, including greater filter loading capacity and higher #exosome yield.
www.roosterbio.com/products/age...
AgentV™-DSP, a solution from RoosterBio, is designed to prevent filter fouling and deliver novel processing advantages, including greater filter loading capacity and higher #exosome yield.
www.roosterbio.com/products/age...
August 26, 2025 at 12:46 PM
The Scalable Solution for 10X Exosome Yield: AgentV-DSP
AgentV™-DSP, a solution from RoosterBio, is designed to prevent filter fouling and deliver novel processing advantages, including greater filter loading capacity and higher #exosome yield.
www.roosterbio.com/products/age...
AgentV™-DSP, a solution from RoosterBio, is designed to prevent filter fouling and deliver novel processing advantages, including greater filter loading capacity and higher #exosome yield.
www.roosterbio.com/products/age...
REPROCELL’s StemRNA™ iPSC Seed Stock Clones for Seamless Translational Research -https://bioinformant.com/reprocells-ipsc-seed-stock-clones/
@reprocell.bsky.social
@reprocell.bsky.social
July 1, 2025 at 1:46 PM
REPROCELL’s StemRNA™ iPSC Seed Stock Clones for Seamless Translational Research -https://bioinformant.com/reprocells-ipsc-seed-stock-clones/
@reprocell.bsky.social
@reprocell.bsky.social
How CellPort Is Making Cell Culture Smarter – Interview with Patrick Dentinger, CEO of CellPort Software
bioinformant.com/patrick-dent...
bioinformant.com/patrick-dent...
March 17, 2025 at 7:00 PM
How CellPort Is Making Cell Culture Smarter – Interview with Patrick Dentinger, CEO of CellPort Software
bioinformant.com/patrick-dent...
bioinformant.com/patrick-dent...
Cellistic Launches Allo Chassis™: Ready-to-use, immune-cloaked #iPSC Cell Lines facilitating cost-effective cell therapy development - bioinformant.com/cellistic-la...
March 3, 2025 at 5:51 PM
Cellistic Launches Allo Chassis™: Ready-to-use, immune-cloaked #iPSC Cell Lines facilitating cost-effective cell therapy development - bioinformant.com/cellistic-la...
Introducing AgentV: The Scalable Solution for 10X Exosome Yield
RoosterBio developed AgentV™-DSP to address filtration problems. It provides advantages such as enabling use of smaller cutoff filters, greater filter loading capacity, and greater #exosome yield.
us02web.zoom.us/webinar/regi...
RoosterBio developed AgentV™-DSP to address filtration problems. It provides advantages such as enabling use of smaller cutoff filters, greater filter loading capacity, and greater #exosome yield.
us02web.zoom.us/webinar/regi...
January 27, 2025 at 8:45 PM
Introducing AgentV: The Scalable Solution for 10X Exosome Yield
RoosterBio developed AgentV™-DSP to address filtration problems. It provides advantages such as enabling use of smaller cutoff filters, greater filter loading capacity, and greater #exosome yield.
us02web.zoom.us/webinar/regi...
RoosterBio developed AgentV™-DSP to address filtration problems. It provides advantages such as enabling use of smaller cutoff filters, greater filter loading capacity, and greater #exosome yield.
us02web.zoom.us/webinar/regi...
MSCs: A Multi-Version Medicinal Technology System lnkd.in/gSgwn3b9
Administered as cell therapies, MSCs’ cumulative clinical trial numbers (>1000) and planned patient enrollments (>60,000) are in a close second place only behind T cells in recent years.
Administered as cell therapies, MSCs’ cumulative clinical trial numbers (>1000) and planned patient enrollments (>60,000) are in a close second place only behind T cells in recent years.
January 6, 2025 at 7:25 PM
MSCs: A Multi-Version Medicinal Technology System lnkd.in/gSgwn3b9
Administered as cell therapies, MSCs’ cumulative clinical trial numbers (>1000) and planned patient enrollments (>60,000) are in a close second place only behind T cells in recent years.
Administered as cell therapies, MSCs’ cumulative clinical trial numbers (>1000) and planned patient enrollments (>60,000) are in a close second place only behind T cells in recent years.
Proudly Supporting Great Science and Women in STEM -https://bioinformant.com/women-in-stem-word-2025/
WORD+ 2025 is pleased to introduce its conference chairs and speakers.
FYI: In February 2025, 60% of session chairs and 54% of speakers will be leading scientists who are female.
WORD+ 2025 is pleased to introduce its conference chairs and speakers.
FYI: In February 2025, 60% of session chairs and 54% of speakers will be leading scientists who are female.
December 10, 2024 at 7:49 PM
Proudly Supporting Great Science and Women in STEM -https://bioinformant.com/women-in-stem-word-2025/
WORD+ 2025 is pleased to introduce its conference chairs and speakers.
FYI: In February 2025, 60% of session chairs and 54% of speakers will be leading scientists who are female.
WORD+ 2025 is pleased to introduce its conference chairs and speakers.
FYI: In February 2025, 60% of session chairs and 54% of speakers will be leading scientists who are female.